Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Acute Coronary Syndrome Patients: A Six-Month Follow-Up Study

Objectives : Carbohydrate antigen 125 (CA125) is associated with different heart conditions. The study aims to determine CA125 levels in patients with ACS and the potential relationship between major adverse cardiac events (MACE) in a short-term following. Methods : This was a prospective and cross-sectional study conducted in the cardiology clinic between May and August 2022. Plasma CA125 levels were measured only once on hospital admission. Patients were followed for six months. The presence of MACE (cardiac death, recurrent ACS, need for revascularization, decompensated heart failure, hypertensive cardiogenic pulmonary edema) was recorded. Results : A total of 127 patients were included in the study. The mean left ventricular ejection fraction (LVEF) was 50.5%. The plasma CA125 median value was 14.6 KU/L. It was determined that there was a positive, significant relationship between CA125 value and hsTroponinT (r=0.315, p<0.001) and proBNP (r=0.423, p<0.001), and a negative relationship between LVEF (r=-0.186, p=0.037) value. Conclusions : It was found that plasma CA125 levels were correlated with ACS biomarkers (proBNP and hs-cTnT). Another interesting result was the correlation with the predictive value LVEF. Elevated plasma CA125 levels might be used to identify patients with ACS with a higher risk of MACE at 6 months.